Karyopharm Therapeutics (NASDAQ:KPTI) Earns “Buy” Rating from HC Wainwright

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $7.00 price target on the stock.

KPTI has been the subject of a number of other reports. Piper Sandler raised their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Royal Bank of Canada restated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Monday, February 10th. Finally, StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Stock Performance

Shares of Karyopharm Therapeutics stock opened at $0.60 on Thursday. The business’s 50 day simple moving average is $0.66 and its 200 day simple moving average is $0.76. Karyopharm Therapeutics has a 52-week low of $0.53 and a 52-week high of $1.70. The firm has a market cap of $75.51 million, a PE ratio of -0.59 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The firm had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. As a group, equities research analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KPTI. Adage Capital Partners GP L.L.C. boosted its stake in shares of Karyopharm Therapeutics by 46.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock worth $4,274,000 after acquiring an additional 2,000,000 shares during the period. GSA Capital Partners LLP boosted its stake in shares of Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after acquiring an additional 792,283 shares during the period. Jane Street Group LLC boosted its stake in shares of Karyopharm Therapeutics by 265.5% during the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock worth $506,000 after acquiring an additional 543,556 shares during the period. Marshall Wace LLP boosted its stake in shares of Karyopharm Therapeutics by 15.3% during the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock worth $1,633,000 after acquiring an additional 319,187 shares during the period. Finally, Shay Capital LLC bought a new position in shares of Karyopharm Therapeutics during the 4th quarter worth approximately $116,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).